19.32% 0.1585

Avenue Therapeutics Inc (ATXI)

Panoramica Notizia Cronologia dei prezzi Financials Perché ATXI Giù? Forum Previsione Frazionamento azionario

Avenue Therapeutics Inc Borsa (ATXI) Ultime notizie

Avenue Therapeutics Inc (ATXI)

Avenue Therapeutics Inc Borsa (ATXI) Ultime notizie

Avenue Therapeutics Inc. (ATXI) Stock Price | Live Quotes & Charts | OTO - StocksToTrade

Avenue Therapeutics Leads Six-Month Stock Performance with 267.29% Return - Markets Mojo

Esperion Therapeutics Stock Hits Near 1-Year High As Wall Street Sees Strong Risk-Reward Play On Demand For Cholesterol Drug - Stocktwits

Avenue Therapeutics Leads Six-Month Stock Performance with 253.98% Return - Markets Mojo

Avenue Therapeutics Leads Six-Month Stock Performance with 257.7% Return - Markets Mojo

Village Farms International Leads with 276.7% Return in Recent Six Months - Markets Mojo

Avenue Therapeutics Announces 2025 Annual Meeting Date - The Globe and Mail

[8-K] AVENUE THERAPEUTICS, INC. Reports Material Event | ATXI SEC FilingForm 8-K - Stock Titan

Village Farms International Leads with 282% Return in Recent Performance Surge - Markets Mojo

Village Farms International Leads with 275% Return in Recent Performance Surge - Markets Mojo

Axsome Therapeutics stock hits all-time high at 144.19 USD By Investing.com - Investing.com Nigeria

Avenue Therapeutics Leads Six-Month Stock Performance with 333.85% Return - Markets Mojo

Fortress Biotech Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights - The Manila Times

Avenue Therapeutics Reports Improved Financials Amid Challenges - TipRanks

[10-Q] AVENUE THERAPEUTICS, INC. Quarterly Earnings Report | ATXI SEC FilingForm 10-Q - Stock Titan

Avenue Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025 - MarketScreener

Village Farms International Leads Six-Month Stock Performance with 424.66% Return - Markets Mojo

ATXI SEC FilingsAvenue Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan

Avenue Therapeutics Sells Baergic Bio to Axsome - TipRanks

RBC Capital Sticks to Their Buy Rating for Axsome Therapeutics (AXSM) - The Globe and Mail

Village Farms International Leads with 418.66% Return in Recent Performance - Markets Mojo

Village Farms International Leads with 354.34% Return in Recent Performance - Markets Mojo

Axsome Therapeutics acquires Baergic Bio from Avenue Therapeutics - MSN

Axsome Therapeutics Eyes Baergic Bio: Is This the Next Big CNS Breakthrough? - Smartkarma

Axsome Therapeutics Buys Global Rights To AZD7325 To Expand Epilepsy Pipeline - Pulse 2.0

Deutsche Bank Sticks to Its Sell Rating for AstraZeneca (AZN) - The Globe and Mail

Nebius Group NV Leads Six-Month Stock Performance with 359.83% Return - Markets Mojo

Axsome acquires global rights to AstraZeneca’s epilepsy drug candidate By Investing.com - Investing.com Australia

Avenue shares rights to epilepsy drug candidate with Axsome in deal - Investing.com Nigeria

Axsome acquires global rights to AstraZeneca’s epilepsy drug candidate - Investing.com India

Axsome Therapeutics stock hits all-time high at 139.22 USD By Investing.com - Investing.com South Africa

Axsome Therapeutics stock hits all-time high at 139.22 USD - Investing.com India

Avenue Therapeutics (ATXI) Sells Baergic Bio to Axsome Therapeutics - GuruFocus

AZN Secures Deal with Axsome for Epilepsy Drug Development - GuruFocus

Avenue shares rights to epilepsy drug candidate with Axsome in deal By Investing.com - Investing.com South Africa

Axsome Therapeutics IncObtains Exclusive G - 富途牛牛

Axsome Therapeutics Acquires Subtype Selective GABA-A Receptor Positive Allosteric Modulator AZD7325 for the Treatment of Epilepsy - The Manila Times

OTC Markets Group Welcomes SUN SILVER LTD. to OTCQX - The Manila Times

Axsome Therapeutics, Inc. entered into an agreement to acquire Baergic Bio, Inc. from Avenue Therapeutics, Inc. for $79.3 million. - MarketScreener

Global Pain Management Devices Market Set to Expand Rapidly at a CAGR of ~8% by 2032 Amid Growing Preference for Minimally Invasive Solutions | DelveInsight - Business Upturn

Nebius Group NV Leads Six-Month Stock Performance with 374.29% Return - Markets Mojo

OVID PRE 14A: approvals for Series B conversion and warrants - Stock Titan

Can Dianthus Therapeutics Inc. stock attract ESG capital inflowsPortfolio Value Summary & AI Driven Price Forecasts - fcp.pa.gov.br

Lirum Therapeutics Announces FDA 'Study May Proceed” Letter Enabling Inclusion of LX-101 in the RAPID Platform Clinical Trial for Ewing Sarcoma and Desmoplastic Small Round Cell Tumor - The Manila Times

Lirum Therapeutics Announces FDA “Study May Proceed” Letter - GlobeNewswire

Head to Head Survey: Avenue Therapeutics (NASDAQ:ATXI) vs. Neoleukin Therapeutics (NASDAQ:NLTX) - Defense World

Simile a ATXI